Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and the best dose of selumetinib and how well
it works in treating or re-treating young patients with low grade glioma that has come back
(recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.